CervoMed Inc (CRVO)
18.69
-0.24
(-1.27%)
USD |
NASDAQ |
May 24, 16:00
18.58
-0.11
(-0.59%)
After-Hours: 20:00
CervoMed Cash from Financing (Quarterly)
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -0.0934M |
| September 30, 2023 | 11.24M |
| June 30, 2023 | 0.00 |
| March 31, 2023 | |
| December 31, 2022 | 0.00 |
| September 30, 2022 | -0.005M |
| June 30, 2022 | 0.00 |
| March 31, 2022 | 0.005M |
| December 31, 2021 | 0.00 |
| September 30, 2021 | 0.00 |
| June 30, 2021 | 0.00 |
| March 31, 2021 | 33.30M |
| December 31, 2020 | 0.00 |
| September 30, 2020 | -0.1414M |
| June 30, 2020 | 17.88M |
| March 31, 2020 | 0.1552M |
| December 31, 2019 | 10.48M |
| September 30, 2019 | -0.0802M |
| June 30, 2019 | 5.649M |
| March 31, 2019 | 0.00 |
| December 31, 2018 | 0.00 |
| September 30, 2018 | 0.00 |
| June 30, 2018 | -0.7248M |
| March 31, 2018 | 10.59M |
| December 31, 2017 | -0.028M |
| Date | Value |
|---|---|
| September 30, 2017 | -1.935M |
| June 30, 2017 | 8.005M |
| March 31, 2017 | 14.08M |
| December 31, 2016 | -0.0543M |
| September 30, 2016 | 1.88M |
| June 30, 2016 | 0.00 |
| March 31, 2016 | 0.00 |
| December 31, 2015 | |
| September 30, 2015 | |
| June 30, 2015 | |
| March 31, 2015 | |
| December 31, 2014 | 0.0767M |
| September 30, 2014 | -1.372M |
| June 30, 2014 | 31.61M |
| March 31, 2014 | 0.40M |
| December 31, 2013 | 0.00 |
| September 30, 2013 | 0.51M |
| June 30, 2013 | 0.4175M |
| March 31, 2013 | 0.20M |
| December 31, 2012 | 1.653M |
| September 30, 2012 | 0.6733M |
| June 30, 2012 | 0.437M |
| March 31, 2012 | 1.761M |
| December 31, 2011 | 1.186M |
| September 30, 2011 | 0.784M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-0.1414M
Minimum
Sep 2020
33.30M
Maximum
Mar 2021
4.354M
Average
--
Median
Dec 2020
Cash from Financing (Quarterly) Benchmarks
| GlucoTrack Inc | -- |
| AIM ImmunoTech Inc | 2.829M |
| Perspective Therapeutics Inc | 166.33M |
| Protalix BioTherapeutics Inc | 0.00 |
| Armata Pharmaceuticals Inc | 34.93M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -1.424M |
| Free Cash Flow | -7.392M |
| Free Cash Flow Per Share (Quarterly) | -0.2307 |
| Free Cash Flow Yield | -9.32% |